Table 1 Characteristics of ALA in patients with or without HIV infectiona
HIV-negative (n = 5) | HIV-Infected (n = 28) | Pvalue | |
|---|---|---|---|
Mean age, years | 44.2 ± 10.3 (30–57) | 36 ± 10.1 (23–70) | |
Male/Female | 5/0 | 28/0 | 1 |
IHA titer | 512–16384 | <8–16,384 | |
Underlying diseases | |||
Diabetes mellitus | 20% (1) | 0 (0) | 0.15 |
HBV hepatitis | 20% (1) | 32% (9) | 1 |
HCV hepatitis | 0 (0) | 14% (4) | 1 |
Risk factors | |||
Endemic traveling | 80% (4) | 14% (4) | 0.08 |
Clinical manifestation | |||
Fever | 100% (5) | 64% (18) | 0.29 |
RUQ pain | 40% (2) | 57% (16) | 0.64 |
Diarrhea | 20% (1) | 36% (10) | 0.64 |
Right flank pain | 20% (1) | 11% (3) | 0.5 |
Concurrent colitis | 40% (2) | 18% (5) | 0.28 |
Laboratory data | |||
IHA titer | 1:512 ~1:16,384 | 1:8~1:16,384 | |
WBC/μL | 19,476 ± 9,363 | 11,982 ± 7,854 | 0.02 |
GOT U/L | 156 ± 251 | 52 ± 44 | 0.94 |
GPT U/L | 106 | 76 ± 124 | 0.30 |
Alkaline phosphatase, U/L | 376 ± 324 | 337 ± 175 | 0.46 |
Complications | |||
Peritonitis | 0% (0) | 11% (3) | 1 |
Pleural effusions | 0% (0) | 18% (5) | 0.57 |
Treatment | |||
Mean Metronidazole use duration (days) | 16.8 ± 3.7 | 14.4 ± 5.6 | 0.17 |
Follow-up with idoquinolone | 20% (1) | 79% (22) | 0.01 |
Outcome | |||
Recurrence of ALA | 20%(1) | 7.1% (2) | 0.4 |
Mortality | 0% (0) | 0% (0) |